肝动脉与门静脉双介入治疗中晚期原发性肝癌临床研究

目的研究与探讨肝动脉及门静脉双介入化疗栓塞对治疗原发性中晚期肝癌的可行性及临床疗效。方法86例中晚期肝癌患者分为A、B两组，A组应用肝动脉与门静脉双介入灌注化疗及栓塞（TACE＋SPVE）方法治疗患者43例，B组单纯采用肝动脉灌注化疗及栓塞（TACE）方法治疗患者43例。结果A、B两组的近期有效率分别为86．1％和69．8％，治疗后获得二期手术切除率两组分别为16．2％和4．7％，差异有显著性意义（P〈0．05）。治疗后0．5、1、2年生存率，A组为90．6％、62．8％、53．5％，B组为72．1％、48．8％、39．5％，两组间差异有显著性意义（P〈0．05）。并发症方面两组之间无显著性差异。结论应用肝动脉与门静脉双介入治疗中晚期原发性肝癌，优于单纯肝动脉介入治疗的效果。

Double Interventional Therapy Through Hepatic Artery and Portal Vein in Middle or Advanced Stage Hepatocellular Carcinoma of Clinical Application

Objective To investigate the clinical research and effectiveness in double interventional therapy of middle or advanced stage hepatocellular carcinoma through liver arterial and portal vein. Methods Total of 86 patients of middle or advanced stage hepatocellular carcinoma divided into two groups. Group A double interventional therapy through liver arterial and portal vein chemotherapy and embolization 43 patients, Group B alone interventional therapy through liver arterial chemotherapy and embolization 43 patients.Results The Short-term effective rate was 86.1% and 69.8% in group A and group B, The Secondary operation rate was 16.2% and 4.7% in group A and group B, there was a significant difference between the two groups (P<0.05). The half-1-and 2- year survival rate were 90.6%,62.8% and 53.5% in group A, but 72.1%,48.8% and 39.5% in group B, there were significant differences the two groups (P<0.05). There was no marked difference in incidence rate of complications between the two groups (P>0.05). Conclusion The therapeutic effect of double interventional therapy through liver arterial and portal vein on middle or advanced stage hepatocellular carcinoma, is better than that of alone interventional therapy through liver arterial.